Chronic hyperglycaemia drives functional impairment of lymphocytes in diabetic INS^{C94Y} transgenic pigs

Isabella-M. Giese [1], Simone Renner [2,3,4], Eckhard Wolf [2,3,4,5], Stefanie M. Hauck [4,6], Cornelia A. Deeg [1*]

[1] Chair of Physiology, Department of Veterinary Sciences, LMU Munich, Germany
[2] Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Germany
[3] Center for Innovative Medical Models (CiMM), Department of Veterinary Sciences, LMU Munich, Germany
[4] German Center for Diabetes Research (DZD), Neuherberg, Germany
[5] Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Germany
[6] Research Unit Protein Science, Helmholtz Center Munich, German Research Center for Environmental Health GmbH, Germany

***Corresponding author:**

Cornelia A. Deeg: Chair of Physiology, Department of Veterinary Sciences, LMU Munich
Lena-Christ-Str. 48, D-82152 Martinsried
E-Mail: Cornelia.Deeg@lmu.de
Phone: +49 89 2180-2551

ABSTRACT

People with diabetes mellitus have an increased risk for infections, however, there is still a critical gap in precise knowledge about altered immune mechanisms in this disease. Since diabetic INS^{C94Y} transgenic pigs exhibit elevated blood glucose and a stable diabetic phenotype soon after birth, they provide a favourable model to explore functional alterations of immune cells in an early stage of diabetes mellitus *in vivo*. Hence, we investigated peripheral blood mononuclear cells (PBMC) of these pigs compared to non-transgenic wild-type littermates. We found a 5-fold decreased proliferative response of T cells, disturbed by chronic hyperglycaemia, to polyclonal T cell mitogen phytohaemagglutinin (PHA) and significant increases in mitochondrial oxygen consumption and basal glycolytic activity in PBMC of diabetic pigs. Using LC-MS/MS, we analysed the porcine $CD4^+$ T cell proteome with a total of 2,704 quantified proteins and identified important differences in protein abundances in young diabetic pigs indicating distinct proteomic changes in T cells at initial stage diabetes mellitus.

Keywords: Animal model(s) / Annexin A1 / Diabetes mellitus / Glycolytic rate / Cell metabolism / Oxygen consumption / PHA / Proliferation / T cells / Impaired immune cell function

Abbreviations

ANXA1	Annexin A1
ConA	Concanavalin A
COVID-19	Corona Virus Disease 2019
ERK	Extracellular regulated protein kinases
MAPK	Mitogen-activated protein kinases
PBMC	Peripheral mononuclear cells
PHA	Phytohaemagglutinin
PWM	Pokeweed mitogen
RT	Room temperature
tg	Transgenic

INTRODUCTION

Diabetes mellitus is a major risk factor regarding the outcome of bacterial and viral infections (Harding et al. 2019). Among diabetic patients, increased numbers of highly susceptible individuals suffering from tuberculosis (Kumar et al. 2019) or influenza (Marshall et al. 2020) are common. Recently, meta-analyses revealed an enhanced severity and mortality of COVID-19 infections in people with diabetes mellitus (Zhou et al. 2020; Hu et al. 2020). Undoubtedly, there is a link between the disease and an impaired immune system, but the molecular mechanisms involved in altered immune cell function in diabetic patients are still unknown to date.

Dysfunctional T cells may play a pivotal role in immunological impairment in diabetes mellitus (Nicholas et al. 2019). However, the precise effects of chronic hyperglycaemia on immune cell function are still uncertain since contradictory findings of both hyperresponsive (Nyambuya et al. 2020) and attenuated (Lee et al. 2019; Lau et al. 2019) T cells were reported in type 2 diabetic patients. While numerous studies linked hyperglycaemia to enhanced T cell activation and proliferation (Nyambuya et al. 2020), others suggest that an abnormal glucose homeostasis promotes an insufficient T-cell response via an increased frequency of senescent T cells with proliferative impairment (Lau et al. 2019; Lee et al. 2019). Thus, it has yet to be determined whether dysfunctional T cells are impaired or highly activated in diabetes mellitus and whether hyperglycaemia facilitates immune cell dysregulation.

Alterations of cellular mechanisms and molecular networks in disease states can be analysed by changes in proteome composition (Soongsathitanon, Umsa-Ard, and Thongboonkerd 2019). Still little is known about accurate protein profiles of T cells affected by hyperglycaemia *in vivo*. Therefore, mass spectrometry-based studies are a powerful tool for obtaining comprehensive information regarding cellular pathology (Lepper et al. 2018) and enable hypothesis-generating approaches on the protein level to understand the molecular basis of altered proteome composition and regulation caused by disease.

Moreover, recent advances in the field of immuno-metabolism recognized cellular metabolism as a primary driver and regulator of immune cell function, leading to a wide variety of functionally different immune cells (Olenchock, Rathmell, and Vander Heiden 2017). Since there is still a lack of knowledge about hyperglycaemia-associated alterations of immune cell metabolic phenotypes, there is an urgent need to understand whether and how high glucose levels affect the metabolic phenotype of the cells and thereby change their immune cell function (Olenchock, Rathmell, and Vander Heiden 2017).

Diabetic INS^{C94Y} transgenic (tg) pigs were generated as a large animal model of permanent neonatal diabetes mellitus (Renner et al. 2013). These pigs are characterized by impaired insulin secretion with consecutive hypoinsulinaemia and increased fasting blood glucose levels (Renner et al. 2013). Early on, INS^{C94Y} tg pigs show a stable diabetic phenotype and mirror several disease-associated alterations of diabetes mellitus as seen in humans such as cataract, retinopathy, impaired myocardial function and regeneration (Hinkel et al. 2017; Kleinwort et al. 2017). Since early stages of disease in diabetic patients are often unperceived for a long time, initial immunological alterations are difficult to observe due to the latent disease process. Thus, this diabetic pig model enables the exploration of deviant immune cell function and underlying mechanisms in an early stage of diabetes mellitus with hyperglycaemia and hypoinsulinaemia, offering valuable insights into disease pathogenesis. Hence, we used PBMC of young INS^{C94Y} tg pigs and non-transgenic wild-type littermates to investigate the impact of a permanent early-life hyperglycaemic condition on immune cell function.

RESULTS

Reduced proliferative capacity of lymphocytes in diabetic INS^{C94Y} transgenic pigs after polyclonal stimulation with PHA

For assessment of the proliferation response *in vitro*, we used B- and T cell mitogen PWM (Nam et al. 2019) and the specific T cell mitogens ConA (Rodríguez-Gómez et al. 2019) and PHA (Lin et al. 2016) to stimulate lymphocytes of diabetic INS^{C94Y} tg pigs and wild-type littermates. Interestingly, while no differences could be observed between the two groups after stimulation with PWM (Figure 1A) and ConA (Figure 1B), lymphocytes of diabetic pigs (n=11) revealed a significantly 5-fold decreased proliferation rate in response to PHA compared to wildtypes (n=13) (Figure 1C; ***p≤0.001).



Figure 1. Proliferative capacity of porcine lymphocytes. Mitogens were used for stimulation of lymphocytes analyzed after 48 h of culture: **(A)** pokeweed mitogen (PWM) **(B)** concanavalin A (ConA) or **(C)** phytohaemagglutinin (PHA). Proliferation rate of stimulated lymphocytes did not differ between wild-type (wt, n=12) and INS^{C94Y} tg pigs (n=10) stimulated by ConA and PWM. After PHA-stimulation, lymphocytes of INS^{C94Y} tg pigs (n=11) revealed a significantly 5-fold decreased proliferation rate (***p≤0.001) compared to non-transgenic wild-type littermates (n=13). Data are represented as means ± SEM; horizontal bars indicate group means.

Lymphocyte subpopulation ratio did not differ between wildtypes and diabetic pigs

Next, we examined whether the decreased ability to proliferate correlated with altered lymphocyte subpopulations in diabetic INS^{C94Y} tg pigs. There were no significant differences in the percentage of B or T cell population between wildtypes and diabetic pigs (Supplementary Figure 1A, B). Moreover, measurements of T cell subsets $CD4^+$ (Supplementary Fig 1C), $CD8\alpha^+$ (Supplementary Figure 1D), $CD4^+CD8\alpha^+$ αβT cells (Supplementary Figure 1E) and $SWC5^+$ γδT cells (Supplementary Figure 1F) revealed no differences between both groups.

Proteomic profiling identified disease-associated protein ANXA1 in $CD4^+$ T cells of diabetic INS^{C94Y} transgenic pigs

We characterized the proteomes of porcine $CD4^+$ T cells, which we hypothesized to be the key drivers of impaired proliferation response. Purified $CD4^+$ T cells were examined with differential proteome analyses, using data-independent acquisition LC−MS/MS. A high-resolution proteome with 2,704 identified proteins was obtained (quantified with at least two unique peptides), with 80 proteins significantly different in abundance (*$p < 0.05$; Figure 2A, Supplementary Table 1). Two of these proteins had a ≥ 2-fold difference in abundance, named MYL4 and ANXA1 (Figure 2B). In the whole sample set, ANXA1 was highlighted with highest statistical significance in protein abundance differences between wildtypes and diabetic pigs (***$p < 0.001$). Interestingly, higher levels of ANXA1 were also already described in serum and plasma of type 1 (Purvis et al. 2018) and II diabetes mellitus patients (Purvis et al. 2019b). Therefore, we subsequently focused on ANXA1 to get further information.



Figure 2. Quantitative proteome analyses of porcine CD4$^+$ T cells. (A) Hierarchical cluster analysis of the porcine CD4$^+$ T cell proteome revealed significant differences in protein abundance ($p < 0.05$) in INS^{C94Y} tg pigs (n=4) and non-transgenic littermates (wt, n=5) indicated by their human orthologue gene names. Red color indicates increased and blue color decreased abundances of the identified proteins. **(B)** Volcano plot illustrates quantified proteins (≥2 unique peptides) in CD4$^+$ T cells of INS^{C94Y} tg pigs and wild-types (wt) plotted against the respective statistical significance. The horizontal line indicates the p-value cut-off at 0.05. Proteins with a mean fold change ≥ 2 and $p < 0.05$ are shown in red (MYL4 and ANXA1).

ANXA1 was higher abundant at CD4$^+$T cell outer cell membranes of diabetic INS^{C94Y} transgenic pigs

Flow cytometric analyses confirmed that ANXA1 expression was significantly increased in CD4$^+$ T cells of diabetic INS^{C94Y} tg pigs (n=9) compared to wildtypes (n=11) (*$p \leq 0.05$; Figure 3 A-C). Furthermore, we analysed ANXA1 subcellular localization in purified CD4$^+$ T cells

with immunocytology and flow cytometry. While intracellular ANXA1 levels were equivalent between both groups (Figure 3 D-F; n= 4 per group), ANXA1 was significantly enhanced at the outer cell membrane of $CD4^+$ T cells from diabetic pigs (*p<0.05; Figure 3 G-I; n= 6 per group).



Figure 3. Differential ANXA1 expression in porcine $CD4^+$ T cells. (A-C) Representative flow cytometric images of $ANXA1^+CD4^+$ T cells of a wild-type **(A)** and an INS^{C94Y} tg pig **(B)** are shown with reduced ANXA1 expression in wild-type $CD4^+$ T cells. **(C)** Scatter plots summarising flow cytometry analyses of PBMC of eleven wild-type and nine INS^{C94Y} tg pigs. ANXA1 was significantly elevated in $CD4^+$ T cells of INS^{C94Y} tg pigs (*$p < 0.05$). **(D-F)** Similar intracellular ANXA1 levels in purified $CD4^+$ T cells of a wild-type **(D)** and an INS^{C94Y} tg pig

(E) shown by immunofluorescence staining for ANXA1 (red), CD4 (green) and nucleus (blue, counterstained with DAPI) and confirmed by flow cytometry using n=4 per group **(F)**. **(G-I)** Representative images of immunofluorescence staining for ANXA1 on the outer cell membrane of porcine $CD4^+$ T cells demonstrate higher ANXA1 expression in $CD4^+$ T cells of the INS^{C94Y} tg pig **(H)** compared to the wild-type **(G)** (arrows). **(I)** A higher ANXA1 expression on the cell surface of diabetic $CD4^+$ T cells compared to $CD4^+$ T cells of wild-types was confirmed by flow cytometry (n=6 per group). Horizontal bars indicate group means.

Pathway enrichment analyses of $CD4^+$ T cells highlight lipophagy pathway in the diabetic condition

To detect altered biological pathways in diabetic immune cells, we performed pathway enrichment analyses via the Reactome database (Jassal et al. 2020). The most significant pathways enriched in $CD4^+$ T cells of wildtypes were “Lagging strand synthesis”, “Gap-filling DNA repair synthesis and ligation in GG-NER“ and “Polymerase switching” (Table 1). In contrast, proteins with significantly higher abundances in $CD4^+$ T cells of INS^{C94Y} tg pigs were associated with the pathways “Downstream signal transduction”, “RUNX1 regulates transcription of genes involved in differentiation of myeloid cells” and “Lipophagy” (Table 2). Since lipophagy is linked to metabolic dysfunction of immune cells (Kounakis et al. 2019; Tian et al. 2019), and it was recently shown that functional different cell subtypes can be identified solely by their metabolic phenotypes (Olenchock, Rathmell, and Vander Heiden 2017), we next analysed metabolic profiles of the T cells.

Most significant pathways enriched in CD4^{+} T cells of wild-types		
Pathway name	**p-value**	**Identified proteins**
Lagging Strand Synthesis	2.00e-12	POLD1, POLD2, POLD3, RFC2, RFC3
Gap-filling DNA repair synthesis and ligation in GG-NER	2.69e-12	XRCC1, POLD1,POLD2, POLD3, RFC2, RFC3
Polymerase switching	4.45e-12	POLD1,POLD2, POLD3, RFC2, RFC3

Table 1. Pathway Enrichment Analysis of CD4+ T cells from wild-types.

Most significant pathways enriched in CD4^{+} T cells of INS^{C94Y} tg pigs		
Pathway name	**p-value**	**Identified proteins**
Downstream signal transduction	4.37e-04	NCK1, PTPN11
RUNX1 regulates transcription of genes involved in differentiation of myeloid cells	8.92e-04	PRKCB
Lipophagy	0.001	PLIN3, PRKAB1

Table 2. Pathway Enrichment Analysis of CD4+ T cells from INS^{C94Y} tg pigs.

Increased basal glycolytic activity and mitochondrial respiration in PBMC of diabetic pigs

Interestingly, the basal glycolytic rate of PBMC from diabetic pigs was significantly higher compared to wild-type PBMC (Figure 4A; *p<0.05), indicating increased lactate production and glycolytic activity of diabetic PBMC. Furthermore, analyses of OCR revealed a significant increase in oxygen consumption at all measured time points in diabetic pigs. Compared to wild-type PBMC, a rise of basal, ATP-linked and maximal mitochondrial respiration (**p<0.01) as well as spare respiratory capacity (*p<0.05) was present in PBMC from diabetic pigs (Figure 4B). These differences indicated a fundamentally different metabolic phenotype of PBMC from wildtypes (n=15) and diabetic INS^{C94Y} tg pigs (n=10).



Figure 4. Basal glycolytic and mitochondrial respiratory profiles of porcine PBMC. (A) Basal glycolytic rate (Extracellular acidification rate, ECAR) was significantly elevated in PBMC of INS^{C94Y} tg pigs (n=10) compared to wild-type littermates (wt, n=15) (*p<0.05, Student's *t* test) **(B)** Oxygen consumption rate (OCR) was measured under basal conditions and after injection of oligomycin, FCCP, rotenone and antimycin A. Compared to PBMC from wild-types (wt, n=15), mitochondrial respiration of PBMC from diabetic pigs (n=10) yielded a significantly increased basal, ATP-linked and maximal respiration (**p<0.01) as well as a significantly increased spare respiratory capacity (*p<0.05). Data are represented as means ± SEM.

DISCUSSION

To assess the impact of permanent hyperglycaemia on immune cell function *in vivo*, we characterised lymphocytes of a transgenic pig model for permanent neonatal diabetes mellitus. Significant differences in proliferative response, $CD4^+$ T cell proteomes and the metabolic phenotypes were already detectable in these early diabetic pigs. Our findings point to main distinct changes in the T cell compartment triggered by early-life high blood glucose and indicate that several immune alterations already occur in the early stage of diabetes mellitus.

We observed no differences of lymphocyte proliferation between controls and diabetic pigs after polyclonal stimulation with B and T cell mitogen PWM and T cell mitogen ConA. However, after polyclonal stimulation with T cell mitogen PHA, we detected a distinct decreased proliferation of lymphocytes from diabetic pigs, which points to an impaired immune response selectively induced by this mitogen. Interestingly, a decreased response of T cells to PHA-stimulation was already demonstrated in diabetic patients (Chang and Shaio 1995; Richard et al. 2017). The significantly reduced proliferation to PHA was correlated with a decreased interleukin (IL)-2 production (Richard et al. 2017). The cytokine IL-2, as well as its IL-2 receptor, is a cytokine crucial for proliferation processes in human T cells (Abbas et al. 2018) and, thus, is enhanced in these cells after PHA stimulation leading to cell proliferation (Hu et al. 2019). These findings were supported and extended by another transcriptomic study of PHA-activated human $CD4^+$ and $CD8^+$ T cells with decreased gene expression of IL-2 and IL-2 receptor in diabetic type 2 patients (Stentz and Kitabchi 2007). Furthermore, T cells from these patients exhibited differences in expression of additional genes and gene products like lower expression of genes of insulin signalling pathway and enzymes of the glycolytic pathway (Stentz and Kitabchi 2007), indicating that an impaired immune response in the diabetic context induced by PHA is affected by more than IL-2 signalling. Little is known about the precise signalling pathways and intracellular processes stimulated by PHA and ConA in humans and pigs. However, the impaired immune response selectively induced by PHA in hyperglycaemic

conditions, which is not addressed by polyclonal T cell mitogen ConA (Rodríguez-Gómez et al. 2019), points to PHA-associated cell signalling pathways specifically altered in the diabetic condition. In murine T cells, ConA was shown to bind to surface glycoproteins and with high affinity to the co-stimulatory molecule CD28, leading to enhanced T cell proliferation (Ando et al. 2014). If mechanisms hold true for porcine T cells, hyperglycaemia does not affect CD28 signalling in diabetic pigs. In contrast, PHA is able to mimic the stimulation of T cells via crosslinking of T cell receptor and CD3 complex, which is followed by a sustained calcium influx as an important signal for T cell proliferation (Lin et al. 2016). In the Jurkat T cell line, high glucose levels were shown to inhibit T cell activation via an increase in non-enzymatic glycation of concentration-regulating calcium channels and delayed specific activation of these cells with anti-CD3 monoclonal antibody (Boldizsár et al. 2002). Since alterations of calcium homeostasis were shown in various cell types of diabetic patients (Klec et al. 2019), insufficient calcium-mediated signalling in T cells of diabetic pigs might point to impaired PHA-induced proliferation. Thus, the immune cell calcium homeostasis of diabetic INS^{C94Y} tg pigs merits further investigations in future studies to examine possible correlations to the impaired T cell response in the diabetic cases observed in our study.

To gain deeper insights into hyperglycaemia-associated molecular changes of $CD4^+$ T cells, we analysed the proteome of these cells from diabetic pigs and wildtypes as a hypothesis-generating approach for the dysregulated immune responses. Notably, we obtained a comprehensive proteomic data set for porcine $CD4^+$ T cells with a high resolution of 2,704 identified proteins. Among these, we found a total of 3% (80 proteins) with significantly different protein abundances between both groups, indicating distinct proteome differences in $CD4^+$ T cells from early stage diabetic pigs, functionally associated to DNA damage responses and cell protection, actin cytoskeleton organization and regulation of cellular energy metabolism. While many studies of immune cells from diabetic type 2 patients were performed by a 2D-gelelectrophoresis approach, only significantly altered spots were analysed

subsequently with mass spectrometry (Soongsathitanon, Umsa-Ard, and Thongboonkerd 2019; Giorgi et al. 2017). To our knowledge, there is no in-depth proteomic fingerprint of $CD4^+$ T cells in hyperglycaemic conditions at initial stage of non-immune-mediated cases of diabetes mellitus. Interestingly, the protein with the highest statistical significance and a 2-fold higher abundance in diabetic pigs was ANXA1. This protein identification corresponds to findings in type 1 (Purvis et al. 2018) and type 2 (Purvis et al. 2019a) diabetic patients, where ANXA1 was previously found with increased levels in serum and plasma, pointing to a pivotal, disease-associated alteration of this protein. However, the biological consequence of elevated ANXA1 in diabetes mellitus remains unexplained (Purvis, Solito, and Thiemermann 2019). Early studies in mice have shown that ANXA1 acts as a molecular T cell tuner by increasing the strength of T cell receptor signaling and T cell activation (D'Acquisto et al. 2007). Overexpressed ANXA1 induced the differentiation of naïve T cells to pro-inflammatory Th1 cells with a high expression of INFγ (Huang et al. 2016), promoting an inflammatory milieu. Thus, the higher abundance of ANXA1 in $CD4^+$ T cells of diabetic pigs might indicate an enhanced T cell activation with functional importance of a pro-inflammatory immune response. However, also the opposite effect was shown in ANXA1-deficient mouse $CD4^+$ T cells (Yang et al. 2013). These cells increased their activation, proliferation and inflammation in the absence of ANXA1, suggesting that this protein rather has an anti-inflammatory role and attenuates an exacerbated inflammatory response (Yang et al. 2013). One possible reason is that externalized ANXA1 regulates the extracellular regulated protein kinases (ERK)/mitogen-activated protein kinases (MAPK) signaling pathway via binding to its formyl peptide receptor (FPR) (Purvis et al. 2018). This pathway is important for T cell activity and strongly contributes to T cell activation and proliferation (Liu et al. 2019) and was shown to be activated in hyperglycaemia (Purvis et al. 2018). Treatment of *Anxa1*$^{-/-}$ mice with human recombinant ANXA1 attenuated inflammatory processes in tissues by reducing MAPK signaling (Purvis et al. 2018). Thus, a higher abundance of ANXA1 in diabetic $CD4^+$ T cells may temper signaling to protect the cell from

hyperresponsiveness initiated by chronic hyperglycaemia and, thus, exert anti-inflammatory effects. Although we cannot yet define the precise role of ANXA1 in $CD4^+$ T cells in the porcine diabetic model, the identification of ANXA1 in humans and pigs, independent of aetiology, is an important finding which underscores a crucial role of this protein in T cell impairment accompanying diabetes mellitus. It furthermore highlights the potential translational quality of this animal model for diabetes research, which is, in our opinion, recommended for future studies to examine the role of this molecule for the observed dysregulated immune responses. Interestingly, one of the most over-represented pathways of altered proteins in $CD4^+$ T cells of diabetic pigs was lipophagy. Lipophagy is linked to metabolic dysfunctions of cells (Kounakis et al. 2019; Tian et al. 2019), and thus, pointed to an altered metabolic phenotype in diabetic pigs. We therefore characterised the metabolic immune cell phenotype of PBMC, since cellular metabolism can be a primary driver and regulator of immune cell function (Olenchock, Rathmell, and Vander Heiden 2017). Metabolic properties of diabetic PBMC in this study revealed an increase in mitochondrial respiration and basal glycolytic activity. We found significant increases in mitochondrial oxygen consumption rate (OCR) in PBMC of diabetic pigs. Interestingly, in line with our findings, increased oxygen consumption was also demonstrated in PBMC of type 2 diabetes patients (Hartman et al. 2014). Previously, this group also measured a higher production of reactive oxygen species (ROS) in these cells and hypothesised mitochondrial damage in diabetic PBMC caused by enhanced oxidative stress (Widlansky et al. 2010). Since ROS synthesis is essential for physiological immune activation of lymphocytes but lead to cellular damage if concentration surpasses (Alfatni et al. 2020), this parameter should be determined in PBMC of diabetic pigs, in order to evaluate whether immune cells are impaired by oxidative cell stress. On the contrary, mitochondrial respiration with increased oxygen consumption is used by immune cells to supplement increased glycolysis, which is the main metabolic pathway fueling effector function upon T cell activation (Gaber et al. 2019). Besides increased oxygen consumption rates, we also found a higher basal glycolytic

activity in early diabetic pigs, suggesting that hyperglycaemia induced metabolic adaption to local conditions of immune cells and promoted a more activated status in T cells (Bonacina et al. 2019). A rapid increase in glycolysis is an important determinant in cellular energy production and required for effective cell proliferation, size expansion, and differentiation (Gaber et al. 2019). Hence, it is also possible that PBMC in young diabetic pigs are highly metabolically active to challenge hyperglycaemic conditions. Our findings indicate that metabolic disturbances occurring at early stage diabetes mellitus, as observed in INS^{C94Y} tg pigs, likely cause metabolic reprogramming in PBMC and may also influence their activation status. Since further studies are absolutely required for a better understanding of bioenergetic profiles of PBMC in diabetes mellitus, diabetic pigs enable to define mitochondrial properties and cellular energy production in these cells at initial stage of disease.

Taken together, our findings point to an early, fundamental dysregulation of immune cells when exposed to prolonged high blood glucose. Chronic hyperglycaemia leads to profound molecular and functional changes of T cells reasoned by proteomic and metabolic alterations, and, moreover, affects T cell immune responses *in vitro*. Diabetic pigs qualify for additional translational experiments to explore the crucial role of altered ANXA1 levels in adaptive immunity in diabetes mellitus. The altered metabolic properties of immune cells in young diabetic pigs provided novel information on distinct immune cell metabolism at initial stage of disease. The exact meaning of this significantly altered metabolic phenotype of the immune cells is not known so far, thus, INS^{C94Y} tg pigs are a valuable source to further analyse respective changes for the diagnosis, or treatment or even prevention of early stage diabetes mellitus and its immune system-related complications.

MATERIALS AND METHODS

Animal model and sample preparation

In this study, PBMC of 23 sex-matched diabetic INS^{C94Y} tg pigs and 31 non-transgenic wild-type littermates at the age of 12 weeks were used. INS^{C94Y} tg pigs were generated previously as described and exhibited significantly elevated random blood glucose levels within 24 h after birth compared with their non-transgenic wild-type littermates (Renner et al. 2013). All animals were housed under controlled conditions, had free access to water and were fed a commercial diet. For sampling, pigs were fasted overnight and heparinized venous whole blood was collected. PBMC were isolated by density gradient centrifugation (RT, 500 x g, 25 min, brake off) with Pancoll separating solution (PAN-Biotech, Aidenbach, Germany), and restored in PBS (pH 7.4) or RPMI medium (PAN-Biotech, Aidenbach, Germany), supplemented with 10% heat-inactivated foetal calf serum (FCS) and 1% penicillin/streptomycin (both Biochrom, Berlin, Germany). Blood withdrawal was performed according to the German Animal Welfare Act with permission from the responsible authority (Government of Upper Bavaria), following the ARRIVE guidelines and Directive 2010/63/EU.

Lymphocyte stimulation by mitogens

In addition to unstimulated controls, PBMC were either stimulated by pokeweed mitogen (PWM; 1µg/ml), concanavalin A (ConA; 1µg/ml) or phytohaemagglutinin (PHA; 1µg/ml). After an incubation period of 32 hours at 37°C, cells were incorporated with ^{3}H-thymidine (Perkin Elmer, Hamburg, Germany) and incubated for 16 more hours. After harvesting, ^{3}H-thymidine incorporation was quantified by detecting counts per minute (cpm), using a Microbeta (Perkin Elmer, Hamburg, Germany). Proliferation rate was expressed as factor of ^{3}H-thymidine incorporation with respect to unstimulated cells.

Flow cytometry

Staining of $2x10^5$ cells per well was performed with mouse anti-human CD79α (clone HM57, Bio-Rad AbD Serotec, Puchheim, Germany, 1:100) for identification of B cells and Alexa Fluor 647-conjugated rat anti-human CD3ε (clone CD3-12, 1:200; cross-reactive to pig (Czajka et al. 2015)) for identification of T cells. We used FITC-conjugated mouse anti-pig CD4 alpha (clone MIL17, Bio-Rad AbD Serotec, Puchheim, Germany, 1:20) and Alexa Fluor 647-conjugated mouse anti-pig CD8α (clone 76-2-11, Becton Dickinson, Heidelberg, Germany, 1:400) to identify αβT cells and mouse anti-pig SWC5 (clone b37c10, Bio-Rad AbD Serotec, Puchheim, Germany, 1:100) for identification of γδT cell subpopulation. If necessary, a secondary antibody was used (Alexa Fluor 647-conjugated goat F(ab')2 anti-mouse IgG (Fc), Dianova, Hamburg, Germany, 1:1000). Analyses were performed with MACSQuant Analyzer 10 and Flowlogic Software (both Miltenyi Biotec, Bergisch Gladbach, Germany).

Magnetic activated cell sorting (MACS) for $CD4^+$ T cells

Briefly, a total of 6×10^7 cells was incubated in staining buffer with mouse anti-pig CD4 alpha (clone MIL17, Bio-Rad AbD Serotec, Puchheim, Germany, 1:50) at 4°C for 20 min. Staining buffer contained phosphate-buffered saline (pH 7.2) and was supplemented with 2 mM EDTA and 0.5% bovine serum albumin (BSA). In the next step, cells were resuspended in 480 µL staining buffer before adding 120 µL anti-mouse $IgG_{2a/b}$ MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) for an incubation period of 15 min. In further steps, BSA in staining buffer was omitted to prevent interference with mass spectrometry. Magnetic separation was performed using LS columns (Miltenyi Biotec, Bergisch Gladbach, Germany). Magnetically-labelled $CD4^+$ T cells were retained in the magnetic field, while unwanted cells were eliminated by three washing steps. Positive $CD4^+$ T cell fraction was eluted by removing the column from magnetic field and flushing with staining buffer. 6×10^5 positive selected cells

were pelleted and stored at −20 °C until filter-aided sample preparation (FASP). The isolation of porcine $CD4^+$ T cell routinely achieved >90% purity, confirmed by flow cytometry.

Mass spectrometry and data analysis

Purified $CD4^+$ T cells of four diabetic INS^{C94Y} tg pigs and five littermate wildtypes were analyzed. $CD4^+$ T cell pellets were lysed in urea buffer (8M in 0.1M Tris/HCl pH 8.5) and 10 µg total protein of each sample was proteolysed with LysC and trypsin by a modified filter-aided sample preparation (FASP) as described (Grosche et al. 2016). Acidified eluted peptides were analyzed in the data-independent acquisition mode on a Q Exactive HF-X mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) online coupled to an ultra-high-performance liquid chromatography (UHPLC) system (Ultimate 3000, Thermo Fisher Scientific). The spectral library was generated directly in Spectronaut Pulsar X (Biognosys, Schlieren, Switzerland; version 12.0.20491.17.25792) as described (Singh et al. 2020). Spectronaut was equipped with the Ensembl Pig Database (Release 75 (Sscrofa10.2), 25,859 sequences, https://www.ensembl.org). Peptide identification was filtered to satisfy an FDR of 1% by the mProphet approach with q-value cut-off at 0.05 (Reiter et al. 2011). Statistical analysis was performed on log2 transformed normalized abundance values using Student's *t*-test. All proteins with $p < 0.05$ were considered significantly different and proteins with INS^{C94Y}/wt ratio ≥ 2.0 were determined as differentially abundant. The heatmap of hierarchical cluster analysis was created with open source software Cluster 3.0 and was illustrated via Java TreeView (version 1.1.6r4, http://jtreeview.sourceforge.net). GraphPad Prism Software (version 5.04) was used to design Volcano plot, and pathway enrichment analysis was done with open source software Reactome (Pathway Browser version 3.6, https://reactome.org).

Quantification of ANXA1 by immunofluorescence staining

To quantify ANXA1 in porcine PBMC, flow cytometric analysis was performed using rabbit anti-human ANXA1 (Thermo Fisher Scienific, Ulm, Germany, 1:100) and Alexa Fluor 647-conjugated goat anti-rabbit IgG H+L (Invitrogen, Karlsruhe, Germany; 1:500). Cross reactivity of anti-human ANXA1 was proved and high sequence homology of porcine ANXA1 was confirmed via BLASTP (https://blast.ncbi.nlm.nih.gov/Blast.cgi). For intracellular staining, PBMC were permeabilized (BD Cytofix/Cytoperm, Becton Dickinson, Heidelberg, Germany) for 20 min at 4°C and washed with washing buffer (BD Perm/Wash, Becton Dickinson, Heidelberg, Germany), diluted in PBS 1:10.

For immunofluorescence staining, purified $CD4^+$ T cells of wild-type and INS^{C94Y} tg pigs were incubated with FITC-conjugated anti-pig CD4 alpha before staining of ANXA1. After fixation with 1 % PFA, cell nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI; Invitrogen, Karlsruhe, Germany, 1:100) for 30 min at RT. 5 x 10^4 cells were transferred to microscope slides and centrifugated (300 x g, 10 min) before coverslip using mounting medium (Serva, Rosenheim, Germany). Visualization of stained targets was performed using a Leica Dmi8 microscope with associated LAS-X-software (Leica, Wetzlar, Germany).

Measurement of OCR and ECAR by Seahorse XFe Analyzer

Metabolic phenotypes of porcine PBMC were determined using a Seahorse XFe Analyzer (Agilent Technologies, Waldbronn, Germany) measuring oxygen consumption rate (OCR), which is attributed to mitochondrial respiration and extracellular acidification rate (ECAR), which can be related to glycolysis (van der Windt, Chang, and Pearce 2016). In accordance with the manufacturer's instructions, sterile XF assay buffer (Seahorse XF RPMI Medium supplemented with 10mM glucose, 2mM L-glutamine, and 1mM pyruvate, pH 7.4; Agilent Technologies, Waldbronn, Germany) was used for experiments. Prior to the start of the assay, sensor cartridges (Agilent Technologies, Waldbronn, Germany) were prepared adding

oligomycin, FCCP and rotenone & antimycin A. A total of 1 x 10^6 PBMC was seeded in 24-well XF24 cell culture microplates (Agilent Technologies, Waldbronn, Germany), while four wells were kept free from cells as background correction. Baseline OCR and ECAR were measured before adding oligomycin, FCCP and rotenone & antimycin A. OCR was reported in units of pmol/minute and ECAR in mpH/minute.

Statistical Analysis

All data are presented as means $\pm$ SEM unless indicated otherwise. Kolmogorow-Smirnov (KS) test was performed for determination of Gaussian distribution. If KS test indicated $p < 0.05$ (no normal distribution), Mann-Whitney U test was used for statistical analysis, while student's *t*-test was used if KS test was $p > 0.05$ (normal distribution). In both tests, statistical probabilities were considered significant at $p < 0.05$. Significances are indicated by asterisks with $*p < 0.05$, $**p < 0.01$ and $***p < 0.001$.

Acknowledgements: The authors thank F. Stetter, M. Weigand and B. Amann from Chair of Physiology, LMU Munich for critical discussions and S. Zettler and A. Hinrichs from Chair for Molecular Animal Breeding and Biotechnology, LMU Munich for assistance in blood withdrawal.

Funding: This work was supported by grants from the Deutsche Forschungsgemeinschaft SPP project 2127 [DFG DE 719/7-1 to C.D., HA 6014/5-1 to S.M.H.] and by the German Center for Diabetes Research [82DZD00802 to E.W and S.R.].

Duality of interest: The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement: CD conceived and designed the experiments; IMG, SH and CD performed the experiments; IMG and SH analysed the data; SR and EW developed and characterized the INS^{C94Y} tg pig model and contributed reagents and materials; IMG and CD wrote the manuscript. All coauthors critically read the manuscript and approved the final version to be published. CD is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Data availability: The data are available on request from the authors.

Additional files:

Supplementary Figure 1

Supplementary Table 1

REFERENCES

Abbas, A. K., E. Trotta, R. Simeonov D, A. Marson, and J. A. Bluestone. 2018. 'Revisiting IL-2: Biology and therapeutic prospects', *Sci Immunol*, 3.

Alfatni, A., M. Riou, A. L. Charles, A. Meyer, C. Barnig, E. Andres, A. Lejay, S. Talha, and B. Geny. 2020. 'Peripheral Blood Mononuclear Cells and Platelets Mitochondrial Dysfunction, Oxidative Stress, and Circulating mtDNA in Cardiovascular Diseases', *J Clin Med*, 9.

Ando, Y., C. Yasuoka, T. Mishima, T. Ikematsu, T. Uede, T. Matsunaga, and M. Inobe. 2014. 'Concanavalin A-mediated T cell proliferation is regulated by herpes virus entry mediator costimulatory molecule', *In Vitro Cell Dev Biol Anim*, 50: 313-20.

Boldizsár, F., T. Berki, A. Miseta, and P. Németh. 2002. 'Effect of hyperglycemia on the basal cytosolic free calcium level, calcium signal and tyrosine-phosphorylation in human T-cells', *Immunol Lett*, 82: 159-64.

Bonacina, F., A. Baragetti, A. L. Catapano, and G. D. Norata. 2019. 'The Interconnection Between Immuno-Metabolism, Diabetes, and CKD', *Curr Diab Rep*, 19: 21.

Chang, Feng-Yee, and Men-Fang Shaio. 1995. 'Decreased cell-mediated immunity in patients with non-insulin-dependent diabetes mellitus', *Diabetes Res Clin Pract*, 28: 137-46.

Czajka, A., S. Ajaz, L. Gnudi, C. K. Parsade, P. Jones, F. Reid, and A. N. Malik. 2015. 'Altered Mitochondrial Function, Mitochondrial DNA and Reduced Metabolic Flexibility in Patients With Diabetic Nephropathy', *EBioMedicine*, 2: 499-512.

D'Acquisto, F., A. Merghani, E. Lecona, G. Rosignoli, K. Raza, C. D. Buckley, R. J. Flower, and M. Perretti. 2007. 'Annexin-1 modulates T-cell activation and differentiation', *Blood*, 109: 1095-102.

Gaber, T., Y. Chen, P. L. Krauss, and F. Buttgereit. 2019. 'Metabolism of T Lymphocytes in Health and Disease', *Int Rev Cell Mol Biol*, 342: 95-148.

Giorgi, Alessandra, Italo Tempera, Giorgia Napoletani, Diego Drovandi, Cinzia Potestà, Sara Martire, Elisabetta Mandosi, Tiziana Filardi, M. Eugenia Schininà, Susanna Morano, Maria d'Erme, and Bruno Maras. 2017. 'Poly(ADP-ribosylated) proteins in mononuclear cells from patients with type 2 diabetes identified by proteomic studies', *Acta Diabetol*, 54: 833-42.

Grosche, A., A. Hauser, M. F. Lepper, R. Mayo, C. von Toerne, J. Merl-Pham, and S. M. Hauck. 2016. 'The Proteome of Native Adult Muller Glial Cells From Murine Retina', *Mol Cell Proteomics*, 15: 462-80.

Harding, Jessica L., Meda E. Pavkov, Dianna J. Magliano, Jonathan E. Shaw, and Edward W. Gregg. 2019. 'Global trends in diabetes complications: a review of current evidence', *Diabetologia*, 62: 3-16.

Hartman, M. L., O. S. Shirihai, M. Holbrook, G. Xu, M. Kocherla, A. Shah, J. L. Fetterman, M. A. Kluge, A. A. Frame, N. M. Hamburg, and J. A. Vita. 2014. 'Relation of mitochondrial oxygen consumption in peripheral blood mononuclear cells to vascular function in type 2 diabetes mellitus', *Vasc Med*, 19: 67-74.

Hinkel, R., A. Howe, S. Renner, J. Ng, S. Lee, K. Klett, V. Kaczmarek, A. Moretti, K. L. Laugwitz, P. Skroblin, M. Mayr, H. Milting, A. Dendorfer, B. Reichart, E. Wolf, and C. Kupatt. 2017. 'Diabetes Mellitus-Induced Microvascular Destabilization in the Myocardium', *J Am Coll Cardiol*, 69: 131-43.

Hu, S., C. W. Chen, S. T. Chen, K. H. Tsui, T. K. Tang, H. T. Cheng, G. S. Hwang, J. W. Yu, Y. C. Li, P. S. Wang, and S. W. Wang. 2019. 'Inhibitory effect of berberine on interleukin-2 secretion from PHA-treated lymphocytic Jurkat cells', *Int Immunopharmacol*, 66: 267-73.

Hu, Y., J. Sun, Z. Dai, H. Deng, X. Li, Q. Huang, Y. Wu, L. Sun, and Y. Xu. 2020. 'Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis', *J Clin Virol*, 127: 104371.

Huang, P., Y. Zhou, Z. Liu, and P. Zhang. 2016. 'Interaction between ANXA1 and GATA-3 in Immunosuppression of CD4(+) T Cells', *Mediators Inflamm*, 2016: 1701059.

Jassal, Bijay, Lisa Matthews, Guilherme Viteri, Chuqiao Gong, Pascual Lorente, Antonio Fabregat, Konstantinos Sidiropoulos, Justin Cook, Marc Gillespie, Robin Haw, Fred Loney, Bruce May, Marija Milacic, Karen Rothfels, Cristoffer Sevilla, Veronica Shamovsky, Solomon Shorser, Thawfeek Varusai, Joel Weiser, Guanming Wu, Lincoln Stein, Henning Hermjakob, and Peter D'Eustachio. 2020. 'The reactome pathway knowledgebase', *Nucleic acids research*, 48: D498-D503.

Klec, Christiane, Gabriela Ziomek, Martin Pichler, Roland Malli, and Wolfgang F. Graier. 2019. 'Calcium Signaling in ß-cell Physiology and Pathology: A Revisit', *Int J Mol Sci*, 20: 6110.

Kleinwort, K. J. H., B. Amann, S. M. Hauck, S. Hirmer, A. Blutke, S. Renner, P. B. Uhl, K. Lutterberg, W. Sekundo, E. Wolf, and C. A. Deeg. 2017. 'Retinopathy with central oedema in an INS (C94Y) transgenic pig model of long-term diabetes', *Diabetologia*, 60: 1541-49.

Kounakis, Konstantinos, Manos Chaniotakis, Maria Markaki, and Nektarios Tavernarakis. 2019. 'Emerging Roles of Lipophagy in Health and Disease', *Frontiers in Cell and Developmental Biology*, 7.

Kumar, N. P., K. F. Fukutani, B. S. Shruthi, T. Alves, P. S. Silveira-Mattos, M. S. Rocha, K. West, M. Natarajan, V. Viswanathan, S. Babu, B. B. Andrade, and H. Kornfeld. 2019. 'Persistent inflammation during anti-tuberculosis treatment with diabetes comorbidity', *Elife*, 8.

Lau, E. Y. M., E. C. Carroll, L. A. Callender, G. A. Hood, V. Berryman, M. Pattrick, S. Finer, G. A. Hitman, G. L. Ackland, and S. M. Henson. 2019. 'Type 2 diabetes is associated with the accumulation of senescent T cells', *Clin Exp Immunol*, 197: 205-13.

Lee, Yong-ho, So Ra Kim, Dai Hoon Han, Hee Tae Yu, Yoon Dae Han, Jin Hee Kim, Soo Hyun Kim, Chan Joo Lee, Byoung-Hoon Min, Dong-Hyun Kim, Kyung Hwan Kim, Jin Won Cho, Won-Woo Lee, Eui-Cheol Shin, and Sungha Park. 2019. 'Senescent T Cells Predict the Development of Hyperglycemia in Humans', *Diabetes*, 68: 156.

Lepper, M. F., U. Ohmayer, C. von Toerne, N. Maison, A. G. Ziegler, and S. M. Hauck. 2018. 'Proteomic Landscape of Patient-Derived CD4+ T Cells in Recent-Onset Type 1 Diabetes', *J Proteome Res*, 17: 618-34.

Lin, Veronica Hui-Chen, Jiann-Jong Chen, Chen-Chung Liao, Shinn-Shing Lee, and Eileen Jea Chien. 2016. 'The rapid immunosuppression in phytohemagglutinin-activated human T cells is inhibited by the proliferative Ca2+ influx induced by progesterone and analogs', *Steroids*, 111: 71-78.

Liu, J., K. Guo, L. Hu, T. Luo, Y. Ma, Y. Zhang, W. Lai, and Z. Guo. 2019. 'ZAP70 deficiency promotes reverse cholesterol transport through MAPK/ERK pathway in Jurkat cell', *Mol Immunol*, 107: 21-28.

Marshall, R. J., P. Armart, K. D. Hulme, K. Y. Chew, A. C. Brown, P. M. Hansbro, C. J. Bloxham, M. Flint, K. Ronacher, H. Bielefeldt-Ohmann, L. A. Gallo, and K. R. Short. 2020. 'Glycemic Variability in Diabetes Increases the Severity of Influenza', *mBio*, 11.

Nam, J. H., B. Cha, J. Y. Park, F. Abekura, C. H. Kim, and J. R. Kim. 2019. 'Mitogen-Induced Interferon Gamma Production in Human Whole Blood: The Effect of Heat and Cations', *Curr Pharm Biotechnol*, 20: 562-72.

Nicholas, Dequina A., Elizabeth A. Proctor, Madhur Agrawal, Anna C. Belkina, Stephen C. Van Nostrand, Leena Panneerseelan-Bharath, Albert R. Jones, Forum Raval, Blanche C. Ip, Min Zhu, Jose M. Cacicedo, Chloe Habib, Nestor Sainz-Rueda, Leah Persky,

Patrick G. Sullivan, Barbara E. Corkey, Caroline M. Apovian, Philip A. Kern, Douglas A. Lauffenburger, and Barbara S. Nikolajczyk. 2019. 'Fatty Acid Metabolites Combine with Reduced β Oxidation to Activate Th17 Inflammation in Human Type 2 Diabetes', *Cell Metab*, 30: 447-61.e5.

Nyambuya, Tawanda Maurice, Phiwayinkosi Vusi Dludla, Vuyolwethu Mxinwa, and Bongani Brian Nkambule. 2020. 'T-cell activation and cardiovascular risk in adults with type 2 diabetes mellitus: A systematic review and meta-analysis', *Clinical Immunology*, 210: 108313.

Olenchock, Benjamin A., Jeffrey C. Rathmell, and Matthew G. Vander Heiden. 2017. 'Biochemical Underpinnings of Immune Cell Metabolic Phenotypes', *Immunity*, 46: 703-13.

Purvis, G. S. D., F. Chiazza, J. Chen, R. Azevedo-Loiola, L. Martin, D. H. M. Kusters, C. Reutelingsperger, N. Fountoulakis, L. Gnudi, M. M. Yaqoob, M. Collino, C. Thiemermann, and E. Solito. 2018. 'Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes', *Diabetologia*, 61: 482-95.

Purvis, G. S. D., M. Collino, R. A. Loiola, A. Baragetti, F. Chiazza, M. Brovelli, M. H. Sheikh, D. Collotta, A. Cento, R. Mastrocola, M. Aragno, J. C. Cutrin, C. Reutelingsperger, L. Grigore, A. L. Catapano, M. M. Yaqoob, G. D. Norata, E. Solito, and C. Thiemermann. 2019a. 'Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes', *Front Immunol*, 10: 571.

Purvis, G. S. D., E. Solito, and C. Thiemermann. 2019. 'Annexin-A1: Therapeutic Potential in Microvascular Disease', *Front Immunol*, 10: 938.

Purvis, Gareth S. D., Massimo Collino, Rodrigo A. Loiola, Andrea Baragetti, Fausto Chiazza, Martina Brovelli, Madeeha H. Sheikh, Debora Collotta, Alessia Cento, Raffaella Mastrocola, Manuela Aragno, Juan C. Cutrin, Chris Reutelingsperger, Liliana Grigore, Alberico L. Catapano, Magdi M. Yaqoob, Giuseppe Danilo Norata, Egle Solito, and Christoph Thiemermann. 2019b. 'Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes', *Front Immunol*, 10.

Reiter, L., O. Rinner, P. Picotti, R. Huttenhain, M. Beck, M. Y. Brusniak, M. O. Hengartner, and R. Aebersold. 2011. 'mProphet: automated data processing and statistical validation for large-scale SRM experiments', *Nat Methods*, 8: 430-5.

Renner, S., C. Braun-Reichhart, A. Blutke, N. Herbach, D. Emrich, E. Streckel, A. Wunsch, B. Kessler, M. Kurome, A. Bahr, N. Klymiuk, S. Krebs, O. Puk, H. Nagashima, J. Graw, H. Blum, R. Wanke, and E. Wolf. 2013. 'Permanent neonatal diabetes in INS(C94Y) transgenic pigs', *Diabetes*, 62: 1505-11.

Richard, C., M. Wadowski, S. Goruk, L. Cameron, A. M. Sharma, and C. J. Field. 2017. 'Individuals with obesity and type 2 diabetes have additional immune dysfunction compared with obese individuals who are metabolically healthy', *BMJ Open Diabetes Res Care*, 5: e000379.

Rodríguez-Gómez, Irene M., Stephanie C. Talker, Tobias Käser, Maria Stadler, Lisa Reiter, Andrea Ladinig, Jemma V. Milburn, Sabine E. Hammer, Kerstin H. Mair, Armin Saalmüller, and Wilhelm Gerner. 2019. 'Expression of T-Bet, Eomesodermin, and GATA-3 Correlates With Distinct Phenotypes and Functional Properties in Porcine γδ T Cells', 10.

Singh, Jasjot, Edgar Kaade, Jan Muntel, Roland Bruderer, Lukas Reiter, Melanie Thelen, and Dominic Winter. 2020. 'Systematic Comparison of Strategies for the Enrichment of Lysosomes by Data Independent Acquisition', *J Proteome Res*, 19: 371-81.

Soongsathitanon, J., W. Umsa-Ard, and V. Thongboonkerd. 2019. 'Proteomic analysis of peripheral blood polymorphonuclear cells (PBMCs) reveals alteration of neutrophil extracellular trap (NET) components in uncontrolled diabetes', *Mol Cell Biochem*, 461: 1-14.

Stentz, Frankie B., and Abbas E. Kitabchi. 2007. 'Transcriptome and Proteome Expressions Involved in Insulin Resistance in Muscle and Activated T-Lymphocytes of Patients with Type 2 Diabetes', *Genomics, Proteomics & Bioinformatics*, 5: 216-35.

Tian, Y., B. Yang, W. Qiu, Y. Hao, Z. Zhang, B. Yang, N. Li, S. Cheng, Z. Lin, Y. C. Rui, O. K. W. Cheung, W. Yang, W. K. K. Wu, Y. S. Cheung, P. B. S. Lai, J. Luo, J. J. Y. Sung, R. Chen, H. Y. Wang, A. S. L. Cheng, and P. Yang. 2019. 'ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy', *Nat Commun*, 10: 3391.

van der Windt, G. J. W., C. H. Chang, and E. L. Pearce. 2016. 'Measuring Bioenergetics in T Cells Using a Seahorse Extracellular Flux Analyzer', *Curr Protoc Immunol*, 113: 3.16b.1-3.16b.14.

Widlansky, M. E., J. Wang, S. M. Shenouda, T. M. Hagen, A. R. Smith, T. J. Kizhakekuttu, M. A. Kluge, D. Weihrauch, D. D. Gutterman, and J. A. Vita. 2010. 'Altered mitochondrial membrane potential, mass, and morphology in the mononuclear cells of humans with type 2 diabetes', *Transl Res*, 156: 15-25.

Yang, Y. H., W. Song, J. A. Deane, W. Kao, J. D. Ooi, D. Ngo, A. R. Kitching, E. F. Morand, and M. J. Hickey. 2013. 'Deficiency of annexin A1 in CD4+ T cells exacerbates T cell-dependent inflammation', *J Immunol*, 190: 997-1007.

Zhou, Fei, Ting Yu, Ronghui Du, Guohui Fan, Ying Liu, Zhibo Liu, Jie Xiang, Yeming Wang, Bin Song, Xiaoying Gu, Lulu Guan, Yuan Wei, Hui Li, Xudong Wu, Jiuyang Xu, Shengjin Tu, Yi Zhang, Hua Chen, and Bin Cao. 2020. 'Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study', *The Lancet*, 395: 1054-62.